AUTHORS
Crawford John Strunk, MD, Samuel Anim, MD2, Mamle Anim, MD3, Consuela Albright, MSN, CNP4, Regina D. Crawford, MD5, Mamie Myo Thant, MD MS6, Luke R. Smart, MD7, Grace Onimoe, MD8, Erin Espinoza, DO9, Annie J Ross-Womack10, Ravi Talati, DO11
AFFILIATIONS
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Case Comprehensive Cancer Center, Cleveland, Ohio, United States
3 Five Rivers Health Centers, Dayton, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 The Ohio State University, Columbus, Ohio, United States
6 The University of Cincinnati, Cincinnati, Ohio, United States
7 Cincinnati Children's Hospital Medical Center, Cincinnati, United States
8 MetroHealth Hospital, Cleveland, Ohio, United States
9 TriHealth Cancer and Blood Institute, Cincinnati, Ohio, United States
10 Ohio Sickle Cell and Health Association, Columbus, Ohio, United States
11 Cleveland Clinic, Cleveland, Ohio, United States
ABSTRACT
Introduction: Sickle cell disease (SCD) is the most common monogenic disorder in the United States. In Ohio, between 3500-4000 patients live with the disease (Hassell, Am J Prev Med 2010); there are several major adult centers and health systems at which patients can receive care. These centers include locations in Cincinnati (2), Dayton (1), Columbus (1), Toledo (2), and Cleveland (3).
Minimum and optimal elements required for an adult sickle cell center were defined by Kanter et al (Blood Advances 2021) and include access to an SCD specialist, pain management plans, and transfusion services including apheresis. While pediatric patients can access specialized sickle cell care at one of six designated state newborn screening follow-up centers, once patients reach adulthood, care becomes fragmented and challenging to obtain, resulting in many patients not accessing care at a sickle cell center at all. Although there have been no formal studies in the state to date, it is likely that challenges in accessing adult SCD comprehensive care in Ohio include limited SCD experts, inability to obtain appropriate pain management services, inadequate emergency department care, and poor transfusion medicine/apheresis services. Therefore, a state-wide initiative is necessary to complement national programs to advance SCD care, since patients and providers in Ohio, regardless of city, face similar constraints in terms of Medicaid coverage, opioid prescription regulations, and access to transfusion services.
This quality improvement project aims to develop the tools to 1) enhance care for the sickle cell community throughout the state, 2) allow people living with SCD to access an SCD expert wherever they live, and 3) create a process to bring people living with SCD back into care with a sickle cell expert.
Methods: Key leaders at each institution throughout the state were identified and contacted to gauge interest in the project. Once key leaders were identified, an organizational meeting of those leaders and the president of the statewide community-based organization Sickle Cell Disease Association of America-Ohio Sickle Cell and Health Association (SCDAA-OSCHA) took place in April 2026. During that meeting, members identified important gaps in access, clinical care, and research. Once gaps in care were elicited and agreed upon, a framework of goals was developed using a consensus process and an action plan were developed.
Results: SCD experts from University Hospital of Cleveland, MetroHealth Hospital (Cleveland), Cleveland Clinic, University of Cincinnati, TriHealth Cancer and Blood Institute (Cincinnati), The Ohio State University Medical Center (Columbus), Five Rivers Health Centers (Dayton) and OSCHA (Columbus) were included in the meeting. Access gaps demonstrated National Alliance of Sickle Cell Centers (NASCC) defined SCD expert care deserts in Toledo and the southeast corner of the state, while overlapping care was noted in the Cleveland area, leading to fragmentation of care and multiple opioid prescriptions. Care gaps included 1) lack of consistent and transferable individualized care plans, 2) insufficient timely and appropriate emergency care, 3) limited access to expert management of acute and chronic inpatient and outpatient pain, 4) uneven disease management based on guidelines developed by NASCC and the American Society of Hematology, and 5) inconsistent criteria for referral of patients to cell and gene therapy as well as follow-up guidelines post gene therapy. Research gaps identified include benefits of buprenorphine for chronic pain, disease modifying use at each center, and individual institution gaps in care. Future goals may include tracking improvement of outcomes for patients living in Ohio compared to other states such as California or Georgia as well as streamlined access to blood bank and antibody history.
Conclusions: This is the first time Ohio adult sickle cell experts have developed a plan to create a statewide sickle cell adult provider network for the optimization and standardization of care for people living with SCD. Next steps include an in-person retreat sponsored by OSCHA to work on the above gaps. This framework could be used by other states with large sickle cell populations to help standardize their care and improve outcomes and quality of life for people living with SCD.
DISCLOSURES
Crawford John Strunk, MD: Pfizer - Consultancy (Includes expert testimony); Spark Healthcare - Consultancy (Includes expert testimony)